

CSL Limited
2007/08 Half Year Result
20 February 2008

Disclaimer

Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about our financial results and estimates, business prospects and products in research that involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Among the factors that could cause actual results to differ materially are the following: the success of research and development activities, decisions by regulatory authorities regarding whether and when to approve our drug applications as well as their decisions regarding labeling and other matters that would affect the commercial potential of our products; competitive developments affecting our current growth products; the ability to successfully market new and existing products in Australia and other countries; difficulties or delays in manufacturing; trade buying patterns, fluctuations in interest and currency exchange rates; legislation or regulations throughout the world that affect product production, distribution, pricing, reimbursement or access; legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement relating to product liability, patent protection or governmental investigations, growth in costs and expenses; and CSL’s ability to protect its patents and other intellectual property throughout the world. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward looking statements.

Subject to any continuing obligations under applicable law or any relevant listing rules of the ASX, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Highlights

Financial

- Total revenue \$1,878m up 20%
 - GARDASIL[®] royalty of \$81m
 - Australian GARDASIL[®] sales \$143m
- NPAT \$349m up 36%
- Operating cashflow \$293m up 57%
- EPS 63.4* cents up 35%
- Interim dividend 23 cents (unfranked)

* After restating comparative period for 3:1 share split undertaken 24 October 2007


Highlights

Operational


- Robust global demand for plasma therapies continues
- Excellent European rollout of GARDASIL[®] by Merck-Sanofi Aventis Joint Venture
- Encouraging uptake of GARDASIL[®] in Australia
- Privigen[®] (10% liquid IVIG) approved July 07 by US FDA
 - launched in US - Feb 08
- Influenza vaccine approved by US FDA
- Rheumatoid arthritis antibody licensed to MedImmune/AstraZeneca (AZ)

Revenue 1H08 – A\$1.9 billion

Top 10 revenue lines account for ~90% of total revenue



Sales - Geographic Breadth



Group Outlook for FY2008

Revenue	\$3.7bn – \$3.8bn
R&D	\$200m – \$220m
Net profit after tax*	\$670m - \$690m
Est. foreign currency NPAT impact	~\$65m - \$70m

(New guidance at FY07 constant currency \$740m – \$760m)

* Subject to:

- *material price & volume movements on core plasma products*
- *GARDASIL royalties*
- *Australian GARDASIL sales*
- *effective tax rate*
- *Currency movements (see Foreign Exchange Sensitivity slide)*

Revised profit growth offsets currency headwind

August '07 - FY07 result announcement

- FY2008 NPAT guidance \$670m – \$700m
“at FY2007 constant FX”

October '07 – AGM

- FY2008 NPAT guidance reaffirmed
“\$65m adverse FX impact if current rates prevail..”
- Adjusted guidance \$605m - \$635m

Today – 1H08 result announcement

- FY2008 NPAT guidance \$670m - \$690m
“Includes est. \$65m - \$70m adverse FX impact”

Human Health Business Unit Performance

- CSL Behring
- Other Human Health
 - CSL Bioplasma
 - CSL Biotherapies
 - CSL Research & Development


CSL Behring

- Sales US\$1,182m (A\$1,361m)
 - Up 18% in \$US or 13% at constant currency
- EBITDA US\$382m, EBITDA margin ~32%
- Strong contribution from core and specialty products
- Optimizing product mix

Privigen®

- Launched in US Feb 2008
- European rollout late calendar 2008 through to mid calendar 2009

CSL Behring – Sales up 18% in \$US




Sales for the 6 month period

* Non therapy sales such as plasma, testing services etc



Immunoglobulins sales up 26% in \$US




Sales for the 6 month period

Highlights

- IVIG product mix, price and volume strength
- First full period of Cytogam[®] sales
- Strong growth in Vivaglobin[®] and Rhophylac[®]
- 20% Liquid SCIG – phase III
- High single digit volume growth expected for FY2008

Critical Care Sales up 22% in \$US




Sales for the 6 month period

Highlights

- Albumin price recovery
- Strong contribution and growth in specialty products such as, Haemocomplettan[®] P, Beriplex[®] P/N and Berinert[®] P

Haemophilia sales up 15% in \$US



Highlights

- Haemate[®] P /Humate-P[®]
 - US patient uptake
 - Increasing ITT sales in Europe
 - 70% of FVIII sales
- Helixate[®] – US patient growth

CSL Bioplasma

Sales A\$123m

- Solid Intragam[®] P sales in Australia
- Growth in specialty products sales
- Manufacturing scheduling benefits 1H08
- Taiwanese Toll fractionation commenced
- Strong Albumin demand and improved pricing in China
- Improved sales volume under existing toll contracts

CSL Biotherapies

Sales A\$267m

GARDASIL[®] Australia – existing program

- Strong first half of GARDASIL sales - \$143m
- School based catch-up program ~50% complete
- 18 to 26 year old GP based catch-up program included pipeline build in first half
- FY2008 sales ~\$200m

RotaTeq[®] launch in Australia

Growth in pharmaceutical products – urology, analgesics



CSL Biotherapies – Influenza Vaccine

- Launch of US Influenza vaccine – late in season
- 3 new vaccine strains advised by WHO

Influenza business development

- Licensure in Germany and Ireland
 - On track to launch in 2008
- Marketing application submitted China State FDA
- Expanded facility
 - US FDA approval anticipated in calendar 2008

GARDASIL[®] - International

Merck's GARDASIL[®] rollout

- GARDASIL[®] now approved in 93 countries
- Launched in 76 countries
- Successfully rolling out in Europe
- ~7m 9-26yo US females have received at least their first dose
- >29m 9-26yo have yet to receive a dose

Merck seeking to expand label

- Adult women through to Age 45
- 9 – 26 year old males

GARDASIL[®] royalties

- \$81m to CSL for first half
- FY2008 estimates* \$163m

* Source: analyst consensus



Product Development - Portfolio Highlights

Privigen®

Compelling features

- Excellent stability profile - 24 month storage at room temp
- Improved production yield over time

Annual Capacity

- 3 million grams currently available
- Additional 10 million gram capacity available 1H calendar 2009
- Further capacity proposed for 2011

Conversion

- Anticipate conversion of ~1m grams in fiscal 2008
- Anticipate majority conversion within 2 years of new capacity

Product Development – Portfolio Highlights cont.

Plasma Therapeutics

- Subcutaneous IG 20% – phase III ongoing
- Berinert® P (C1 Esterase Inhibitor) – positive phase III results
- Pre-clinical proof of principle data for recombinant coagulation factors for extended half life
- Beriplex® P/N approved in Western Europe

ISCOMATRIX® adjuvant


- December 2007 – Merck added 2 additional licences
- Clinical programs continuing
- Influenza ISCOMATRIX® Vaccine – phase IIa clinical study well advanced

Recombinant Proteins

- CSL 360 Acute Myeloid Leukemia – Phase I study ongoing
- IL13R Asthma – licensed to Merck
- GM-CSFR Rheumatoid Arthritis – licensed to MedImmune / AZ - Phase I study initiated

Financial Detail

NPAT 1H08 – up 36% on PCP (46% FX adjusted)



NPAT for the 6 month period

Notable items

Reported NPAT Growth	36%
NPAT on PCP at Const. FX	46%
Effective tax rate	29.0%
1H08 NPAT comparator growth impacted by:	
• 1H07 Sanofi-Aventis settle	\$18m
• 1H07 Inv. Disc. Release	\$12m

Strong Financial Fundamentals

- Cashflow from operations \$293m (up 57%)
- Net debt \$432m
- Gearing 14.3%
- Interest coverage 57x
- Capital invested \$103m

Emphasis of working capital translation to cashflow

General and Admin Expenses / Other Revenue*

Net growth \$59m on PCP a function of:

- *Sanofi-Aventis settlement in 1H07*
- *CSL's GARDASIL[®] royalty obligations*
- *Additional amortisation*
- *Milestone expenses & other revenue offsets*

Growth of \$4m in general and administration expenses on trailing half



* *Other revenue excludes interest and royalty income*

Foreign Currency Headwind FY2008

Foreign Exchange (post tax)

\$m	1H08 Act	2H08 Fcst	FY Fcst
Translation*	20	~10	~30
Transaction	3	~30-35	~35-40
Total	23	~41-47	~65-70

- 1H08 FX impact consistent with August ready reckoner
- Significant movement in USD/CHF currently circa 1.09 (Aug 1.22)
- FY08 impact expected ~\$65m - \$70m

Net profit after tax**

Net profit after tax FY2008 guidance	\$670m - \$690m
Est. foreign currency NPAT impact	~\$65m - \$70m
<i>(New guidance at FY07 constant currency</i>	<i>\$740m – \$760m)</i>

* See slide 26

** Previous FY2008 NPAT guidance \$670 – 700M at FY2007 constant currency

Foreign Exchange Sensitivity

Translation sensitivity to 1% movement in key currency pairs

Translation 2H08 NPAT* only (ie 6 months)

	2H08	1% chg
• AUD/USD	0.90	+/- \$0.5m
• AUD/EUR	0.61	+/- \$2.0m
• AUD/CHF	0.99	+/- <u>\$1.0m</u>
		\$3.5m

Growth Strategy

Global Specialty Bio-pharmaceutical

- HPV Royalties
- GARDASIL®
(Aust)

- Influenza vaccine
- Advanced IG
products

- ISCOMATRIX®
adjuvant
- Improved
products
- Market
Development

- Novel biotech
products
- Novel plasma
products

Research & Development

- Leverage core capabilities
- Strong portfolio of IP
- Deliver phased growth
- New products – unmet medical needs

Appendix

Group Results

Half year ended December	1H08 A\$m	1H07 A\$m	Change %
Sales	1,750.1	1,514.4	
Other Revenue	128.3	53.1	
Total Revenue	1,878.4	1,567.5	20%
Earnings before Interest, Tax, Depreciation & Amortisation	572.8	448.3	28%
Depreciation/Amortisation	72.9	57.6	
Earnings before Interest and Tax	499.9	390.7	28%
Net Interest Expense	8.8	3.8	
Tax Expense	142.4	129.6	
Net Profit	348.7	257.3	36%
Interim Dividend (cents)	23.00	16.33*	
Basic EPS (cents)	63.42	47.05*	

* After restating for 3:1 share split undertaken 24 October 2007

